Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997731 | 0.87 | HIF1A (0.38) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| SCHEMBL23960154 | 0.87 | PTGS1 (0.38) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| SCHEMBL5998920 | 0.87 | HIF1A (0.38) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| SCHEMBL5999116 | 0.87 | HIF1A (0.38) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| Fluacrypyrim SCHEMBL29413955 | 0.86 | HIF1A (0.37) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| Fluacrypyrim SCHEMBL83958 | 0.86 | HIF1A (0.37) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| Fluacrypyrim SCHEMBL682688 | 0.86 | HIF1A (0.37) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| Fluacrypyrim SCHEMBL5997532 | 0.86 | HIF1A (0.37) | HIF1APTGS1PTGS2EDNRBEDNRA | |
| SCHEMBL8347644 | 0.85 | PTGS1 (0.37) | HIF1APTGS1PTGS2CYP1A2RXFP1 | |
| SCHEMBL4089901 | 0.83 | PTGS1 (0.36) | HIF1APTGS1PTGS2EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287527-A1 | Process for producing acrylic acid derivative | NIPPON SODA CO., LTD. (JP) | 2006-12-21 | — | — | US | disclosed |
| US-20040152894-A1 | Process for producing acrylic acid derivative | NIPPON SODA CO. LTD (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1142857-A1 | PROCESSES FOR PRODUCING ACRYLIC ACID DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152894-A1 | Process for producing acrylic acid derivative | OXGR1, GART, HAO2 | HIF1A 1110/4885PTGS1 2168/4885PTGS2 2233/4885 |
| US-20060287527-A1 | Process for producing acrylic acid derivative | APEH, HAAO, ASNS | HIF1A 946/4885PTGS1 2383/4885PTGS2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.